Arrow ErgoPack and AC3 Optimus Product Overview

NeoTract: A Compelling Growth Asset Significant Market Opportunity Exceptional Clinical Data Established Reimbursement Strong Commercial Infrastructure • UROLIFT® BPH Relief. In Sight..M Initial target market 8.5M U.S. BPH drug or drug drop out patients; $30B+ total addressable market 2 randomized controlled trials; 8 single arm studies • >28 peer-reviewed publications 5-year follow-up data published CPT1 code January 2015 The procedure is covered by Medicare and all national and major commercial plans, when medical criteria are met High quality commercial sales force & management team ⚫ Strong IP position and scalable manufacturing 242 22 Teleflex®

View entire presentation